Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
PRGO vs JNJ vs MCK vs CAH vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - General
Medical - Distribution
Medical - Distribution
Medical - Healthcare Plans
PRGO vs JNJ vs MCK vs CAH vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General | Medical - Distribution | Medical - Distribution | Medical - Healthcare Plans |
| Market Cap | $1.61B | $536.23B | $92.15B | $43.59B | $111.40B |
| Revenue (TTM) | $4.18B | $92.15B | $403.43B | $250.55B | $407.90B |
| Net Income (TTM) | $-1.82B | $25.12B | $4.76B | $1.56B | $2.93B |
| Gross Margin | 34.2% | 68.1% | 3.6% | 3.7% | 13.9% |
| Operating Margin | -4.1% | 26.1% | 1.5% | 0.9% | 1.5% |
| Forward P/E | 5.6x | 19.2x | 19.3x | 17.9x | 12.2x |
| Total Debt | $3.97B | $36.63B | $7.39B | $9.35B | $93.59B |
| Cash & Equiv. | $532M | $24.11B | $5.69B | $3.87B | $8.51B |
PRGO vs JNJ vs MCK vs CAH vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| Johnson & Johnson (JNJ) | 100 | 149.6 | +49.6% |
| McKesson Corporation (MCK) | 100 | 474.1 | +374.1% |
| Cardinal Health, In… (CAH) | 100 | 338.7 | +238.7% |
| CVS Health Corporat… (CVS) | 100 | 133.2 | +33.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRGO vs JNJ vs MCK vs CAH vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PRGO is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta 1.18, yield 9.8%, current ratio 2.76x
- Lower P/E (5.6x vs 12.2x)
- 9.8% yield, 10-year raise streak, vs JNJ's 2.2%
JNJ carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.
- Lower volatility, beta 0.06, Low D/E 51.2%, current ratio 1.11x
- 27.3% margin vs PRGO's -43.5%
- +44.8% vs PRGO's -51.2%
- 13.0% ROA vs PRGO's -19.8%, ROIC 20.7% vs 3.7%
MCK ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs CAH's 160.8%
- PEG 0.49 vs JNJ's 34.17
- 16.2% revenue growth vs PRGO's -2.8%
CAH is the clearest fit if your priority is income & stability.
- Dividend streak 20 yrs, beta 0.03, yield 1.1%
- Beta 0.03 vs PRGO's 1.18
Among these 5 stocks, CVS doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs PRGO's -2.8% | |
| Value | Lower P/E (5.6x vs 12.2x) | |
| Quality / Margins | 27.3% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.03 vs PRGO's 1.18 | |
| Dividends | 9.8% yield, 10-year raise streak, vs JNJ's 2.2% | |
| Momentum (1Y) | +44.8% vs PRGO's -51.2% | |
| Efficiency (ROA) | 13.0% ROA vs PRGO's -19.8%, ROIC 20.7% vs 3.7% |
PRGO vs JNJ vs MCK vs CAH vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PRGO vs JNJ vs MCK vs CAH vs CVS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JNJ leads in 1 of 6 categories
PRGO leads 1 • MCK leads 1 • CAH leads 0 • CVS leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JNJ leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS is the larger business by revenue, generating $407.9B annually — 97.6x PRGO's $4.2B. JNJ is the more profitable business, keeping 27.3% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4.2B | $92.1B | $403.4B | $250.5B | $407.9B |
| EBITDAEarnings before interest/tax | $58M | $31.4B | $6.8B | $3.2B | $10.5B |
| Net IncomeAfter-tax profit | -$1.8B | $25.1B | $4.8B | $1.6B | $2.9B |
| Free Cash FlowCash after capex | $108M | $19.1B | $6.0B | $4.4B | $7.4B |
| Gross MarginGross profit ÷ Revenue | +34.2% | +68.1% | +3.6% | +3.7% | +13.9% |
| Operating MarginEBIT ÷ Revenue | -4.1% | +26.1% | +1.5% | +0.9% | +1.5% |
| Net MarginNet income ÷ Revenue | -43.5% | +27.3% | +1.2% | +0.6% | +0.7% |
| FCF MarginFCF ÷ Revenue | +2.6% | +20.7% | +1.5% | +1.8% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.2% | +6.8% | +6.0% | +11.0% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.4% | +91.0% | +37.0% | -19.5% | +63.1% |
Valuation Metrics
PRGO leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 28.7x trailing earnings, CAH trades at a 54% valuation discount to CVS's 62.8x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs JNJ's 34.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.6B | $536.2B | $92.1B | $43.6B | $111.4B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $548.8B | $93.8B | $49.1B | $196.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.14x | 38.43x | 29.25x | 28.72x | 62.81x |
| Forward P/EPrice ÷ next-FY EPS est. | 5.56x | 19.20x | 19.28x | 17.94x | 12.19x |
| PEG RatioP/E ÷ EPS growth rate | — | 34.17x | 0.75x | — | — |
| EV / EBITDAEnterprise value multiple | 7.42x | 18.61x | 18.74x | 16.01x | 13.11x |
| Price / SalesMarket cap ÷ Revenue | 0.38x | 6.04x | 0.26x | 0.20x | 0.28x |
| Price / BookPrice ÷ Book value/share | 0.55x | 7.56x | — | — | 1.47x |
| Price / FCFMarket cap ÷ FCF | 11.12x | 27.02x | 17.63x | 23.56x | 14.27x |
Profitability & Efficiency
MCK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-51 for PRGO. JNJ carries lower financial leverage with a 0.51x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs PRGO's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -50.7% | +31.7% | +3.0% | — | +3.9% |
| ROA (TTM)Return on assets | -19.8% | +13.0% | +5.7% | +2.8% | +1.1% |
| ROICReturn on invested capital | +3.7% | +20.7% | +5.4% | +33.8% | +5.0% |
| ROCEReturn on capital employed | +4.3% | +17.6% | +30.5% | +19.2% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 1.35x | 0.51x | — | — | 1.24x |
| Net DebtTotal debt minus cash | $3.4B | $12.5B | $1.7B | $5.5B | $85.1B |
| Cash & Equiv.Liquid assets | $532M | $24.1B | $5.7B | $3.9B | $8.5B |
| Total DebtShort + long-term debt | $4.0B | $36.6B | $7.4B | $9.3B | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | -7.20x | 48.23x | 33.79x | 6.38x | 2.11x |
Total Returns (Dividends Reinvested)
Evenly matched — MCK and CAH each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, JNJ leads with a +44.8% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -13.5% | +7.9% | -8.5% | -9.5% | +10.6% |
| 1-Year ReturnPast 12 months | -51.2% | +44.8% | +4.6% | +22.0% | +34.7% |
| 3-Year ReturnCumulative with dividends | -58.1% | +46.3% | +106.4% | +127.3% | +36.6% |
| 5-Year ReturnCumulative with dividends | -60.1% | +46.1% | +286.9% | +235.7% | +17.0% |
| 10-Year ReturnCumulative with dividends | -77.7% | +132.3% | +348.1% | +160.8% | +3.5% |
| CAGR (3Y)Annualised 3-year return | -25.2% | +13.5% | +27.3% | +31.5% | +11.0% |
Risk & Volatility
Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.18x | 0.06x | 0.04x | 0.03x | 0.05x |
| 52-Week HighHighest price in past year | $28.44 | $251.71 | $999.00 | $233.60 | $88.63 |
| 52-Week LowLowest price in past year | $9.23 | $146.12 | $637.00 | $137.75 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +41.2% | +88.4% | +75.3% | +79.3% | +98.5% |
| RSI (14)Momentum oscillator 0–100 | 60.9 | 37.1 | 16.2 | 33.2 | 69.3 |
| Avg Volume (50D)Average daily shares traded | 3.4M | 7.0M | 757K | 1.7M | 7.4M |
Analyst Outlook
Evenly matched — PRGO and JNJ each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PRGO as "Hold", JNJ as "Buy", MCK as "Buy", CAH as "Buy", CVS as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 9.0% for CVS (target: $95). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $20.00 | $249.27 | $1006.50 | $249.67 | $95.20 |
| # AnalystsCovering analysts | 36 | 40 | 31 | 33 | 41 |
| Dividend YieldAnnual dividend ÷ price | +9.8% | +2.2% | +0.4% | +1.1% | +3.1% |
| Dividend StreakConsecutive years of raises | 10 | 36 | 17 | 20 | 0 |
| Dividend / ShareAnnual DPS | $1.15 | $4.87 | $2.69 | $2.04 | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.5% | +3.4% | +1.8% | 0.0% |
JNJ leads in 1 of 6 categories (Income & Cash Flow). PRGO leads in 1 (Valuation Metrics). 3 tied.
PRGO vs JNJ vs MCK vs CAH vs CVS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PRGO or JNJ or MCK or CAH or CVS a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 9x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PRGO or JNJ or MCK or CAH or CVS?
On trailing P/E, Cardinal Health, Inc.
(CAH) is the cheapest at 28. 7x versus CVS Health Corporation at 62. 8x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Johnson & Johnson's 34. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — PRGO or JNJ or MCK or CAH or CVS?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: MCK returned +348. 1% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PRGO or JNJ or MCK or CAH or CVS?
By beta (market sensitivity over 5 years), Cardinal Health, Inc.
(CAH) is the lower-risk stock at 0. 03β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 3385% more volatile than CAH relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — PRGO or JNJ or MCK or CAH or CVS?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PRGO or JNJ or MCK or CAH or CVS?
Johnson & Johnson (JNJ) is the more profitable company, earning 15.
8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 1. 0% for CAH. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PRGO or JNJ or MCK or CAH or CVS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Johnson & Johnson's 34. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — PRGO or JNJ or MCK or CAH or CVS?
All stocks in this comparison pay dividends.
Perrigo Company plc (PRGO) offers the highest yield at 9. 8%, versus 0. 4% for McKesson Corporation (MCK).
09Is PRGO or JNJ or MCK or CAH or CVS better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Both have compounded well over 10 years (CAH: +160. 8%, PRGO: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PRGO and JNJ and MCK and CAH and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PRGO is a small-cap income-oriented stock; JNJ is a large-cap quality compounder stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; CVS is a mid-cap income-oriented stock. PRGO, JNJ, CAH, CVS pay a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.